Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | DNM1 | Q05193 | 11/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.74 |
| ▸ | RAD52 | P43351 | 2/20 | 0.74 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.67 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6060691 | 1.00 | HTT (1.00) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL9717078 | 1.00 | HTT (1.00) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL1042396 | 1.00 | HTT (1.00) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL8755589 | 1.00 | HTT (1.00) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL24997195 | 1.00 | HTT (1.00) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL25212141 | 1.00 | HTT (1.00) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL8755049 | 1.00 | HTT (1.00) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL3207790 | 1.00 | HTT (1.00) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL22320220 | 1.00 | HTT (1.00) | HTTDNM1KMT2AHSP90AA1RAD52 | |
| SCHEMBL8755213 | 1.00 | HTT (1.00) | HTTDNM1KMT2AHSP90AA1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2912008-B1 | PROCESS FOR PREPARING 2-METHOXYMETHYL-1,4-BENZENEDIAMINE AND SALTS THEREOF | NOXELL CORP (US) | 2020-08-05 | — | — | EP | claimed |
| EP-2655265-B1 | WATER CLARIFICATION COMPOSITION AND PROCESS | UNILEVER NV (NL) | 2017-02-08 | — | — | EP | claimed |
| EP-2679546-B1 | Water clarification composition and process | UNILEVER NV (NL) | 2014-12-10 | — | — | EP | claimed |
| EP-1431246-B1 | Process for the preparation of layered silicate intercalation compounds and their use | HILTI AG (LI) | 2008-02-13 | — | — | EP | claimed |
| EP-0600718-B1 | Secondary battery | CANON KK (JP) | 2000-04-26 | — | — | EP | claimed |
| US-20260076906-A1 | Nanoparticles for Enhancing Mitochondrial Networks | UNIV NORTHEASTERN (US) | 2026-03-19 | — | — | US | disclosed |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-07-04 | — | — | US | disclosed |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-27 | — | — | US | disclosed |
| WO-2024123633-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20230338411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-2925431-A2 | METHOD FOR PREPARING AN OPTIONALLY FUNCTIONALISED GLASS HAVING BIMODAL POROSITY, AND SAID GLASS | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2015-10-07 | — | — | EP | disclosed |
| US-9090758-B2 | Phase change ink comprising modified naturally-derived colorants | XEROX CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2015036506-A1 | SIMPLIFIED FLUORIMETRIC METHOD FOR ASSESSING THE INFLUENCE OF A CONDITION ON A BIOLOGICAL SAMPLE AND APPLICATIONS OF SAME | LUXOR (FR) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015007800-A1 | METHOD FOR EXTRACTING AND PURIFYING NUCLEIC ACIDS AND BUFFERS USED | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2015-01-22 | — | — | WO | disclosed |
| WO-2014124901-A1 | SOL-GEL METHOD FOR SEPARATING METAL IONS FROM AN AQUEOUS SOLUTION | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2014-08-21 | — | — | WO | disclosed |
| US-20140155625-A1 | Modified Naturally-Derived Colorants For Phase Change Ink Applications | XEROX CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2014083162-A2 | METHOD FOR PREPARING AN OPTIONALLY FUNCTIONALISED GLASS HAVING BIMODAL POROSITY, AND SAID GLASS | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2014-06-05 | — | — | WO | disclosed |
| US-20140152748-A1 | Phase Change Ink Comprising Modified Naturally-Derived Colorants | XEROX CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155625-A1 | Modified Naturally-Derived Colorants For Phase Change Ink Applications | RB1, KAT2A, KAT5 | HTT 186/4885DNM1 2943/4885KMT2A 236/4885 |
| US-20240207178-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | HTT 868/4885DNM1 307/4885KMT2A 4656/4885 |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, NPC1 | HTT 207/4885DNM1 487/4885KMT2A 3397/4885 |
| US-20240216515-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | PNLIP, LIPA, PHOSPHO1 | HTT 2973/4885DNM1 1488/4885KMT2A 4697/4885 |
| US-20260076906-A1 | Nanoparticles for Enhancing Mitochondrial Networks | MFN2, NLN, PSEN2 | HTT 141/4885DNM1 60/4885KMT2A 4770/4885 |
| US-20230338411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | HTT 868/4885DNM1 307/4885KMT2A 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.